Cell Pathways to Present At First Annual Needham & Company Biotechnology Conference.

Business Editors & Health/Medical Writers

BIOWIRE2K

Needham & Company First Annual Biotechnology Conference

HORSHAM, Pa.--(BW HealthWire)--June 3, 2002

Cell Pathways, Inc. (Nasdaq:CLPA) announced today that the company's Chairman and Chief Executive Officer, Robert J. Towarnicki, and Chief Scientific Officer, Rifat Pamukcu, M.D., will present an overview of the company's strategic plans and recent clinical highlights at the Needham & Company First Annual Biotechnology Conference at 11:30 a.m. EDT on Tuesday, June 4, 2002. The conference is being held at The Millennium Broadway Hotel in New York.

"We are pleased to be a part of the First Needham & Company Biotechnology Conference, and feel that it offers Cell Pathways an excellent opportunity to report its corporate and clinical progress before an audience of institutional investors interested in biotechnology companies," commented Towarnicki.

A live audio webcast will be available during the presentation and can be accessed via the following link: http://www.twst.com/econf/mm/needham2/clpa.html. Replays will be available two hours after the presentation, and can be accessed at Cell Pathways' Investor Relations web site at http://www.cellpathways.com. The webcast will be available for 30 days.

Cell Pathways, Inc., headquartered in Horsham, Pa., is a development stage pharmaceutical company focused on the research and development of novel and unique medications to treat and prevent cancer and to treat certain inflammatory diseases. The company additionally markets and sells oncology-related products made by others. The company's initial drug candidates in clinical development are Aptosyn(R) (exisulind) and CP461. For additional information on Cell Pathways, Inc., visit the Company's web site at http://www.cellpathways.com.

Certain statements made herein, and oral statements made in respect hereof, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These risks are detailed in the Company's reports filed from time to time under the Securities Act of 1933 and/or the Securities Exchange Act of 1934. You are encouraged to read these filings as they are made. They are available over the Internet from the SEC in its EDGAR database. Investors are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. No forward-looking statement can be guaranteed; actual future results may vary materially. Both forward-looking statements and statements of historic fact must be understood in the context of the risks referred to above which characterize the Company's development stage business. The Company undertakes no obligation to update or revise the statements made herein or the factors, which may relate thereto.